|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
4.650 -0.055 (-1.169%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 134,457,581 | 1.965% | 269,574,326 | 257,673,256 | 244,703,884 | 218,182,994 |
| Cost of Sales | (112,923,458) | 2.325% | (225,066,480) | (216,984,387) | (206,366,398) | (184,563,943) |
| Gross Profit | 21,534,123 | 0.114% | 44,507,846 | 40,688,869 | 38,337,486 | 33,619,051 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 134,088 | 18.415% | 261,964 | 368,014 | 417,106 | 332,341 | |
| Profit / (Loss) before Taxation | 6,444,776 | 0.449% | 11,795,812 | 10,929,922 | 9,880,227 | 8,361,081 | |
| Taxation | (1,421,271) | 4.327% | (2,142,804) | (2,526,679) | (2,105,224) | (1,703,152) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (2,836,873) | -4.686% | (5,607,540) | (5,052,386) | (3,920,756) | (3,157,659) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,186,632 | 5.264% | 4,045,468 | 3,350,857 | 3,854,247 | 3,500,270 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 708,602 | -3.592% | 1,542,559 | 1,600,779 | 1,798,626 | 1,732,289 |
| Depreciation & Amortisation | 2,122,917 | 12.469% | 4,082,256 | 3,356,710 | 3,164,365 | 2,558,441 |
| Directors' Emoluments | -- | -- | 7,507 | 8,744 | 8,088 | 11,224 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 35.000 | 6.061% | 64.000 | 53.000 | 61.000 | 56.000 |
| DPS (cts) | 8.700 | -- | 19.400 | 13.500 | 15.400 | 14.292 |
| Dividend Payout Ratio (%) | 24.857% | -- | 30.313% | 25.472% | 25.246% | 25.522% |
| Cash flow per share ($) | -- | -- | 3.259 | 2.791 | 2.475 | 1.722 |
| NBV per share ($) | 8.404 | -- | 8.183 | 7.679 | 7.315 | 6.933 |
| Remarks: | Real time quote last updated: 25/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,186,632 |
| %Change | 5.264% |
| EPS / (LPS) | RMB 0.350 |
| NBV Per Share (¥) | RMB 8.404 |